Should I Buy ABVC? ABVC 2026 Analysis

Should You Buy ABVC Biopharma Inc (ABVC) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

1.740

1 Day change

8.75%

52 Week Range

5.480

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now for an impatient trader: the trend is still bearish (stacked bearish moving averages + weakening MACD), and price is sitting on/just below near-term support (~1.899), which increases breakdown risk.
Upside is more speculative than technical: a bounce is possible because RSI is very low, but there is no proprietary buy signal and options imply extreme uncertainty.
Best action right now based on the data: HOLD / avoid new buys until price reclaims the pivot (~2.025) and stabilizes.

Intellectia Proprietary Trading Signals

AI Stock Picker: no signal on given stock today.
SwingMax: No signal on given stock recently.

Technical Analysis

Trend: Bearish (SMA_200 > SMA_20 > SMA_5), suggesting rallies are likely to be sold.
Momentum: MACD histogram is negative (-0.0073) and negatively expanding, indicating downside momentum is still building.
RSI (6): 26.98 (deeply weak/near oversold conditions); this can enable short bounces, but it is not a reversal confirmation by itself.
Key levels:
- Support: S1 ~1.899 (price ~1.897 is essentially on support), then S2 ~1.821.
- Resistance: Pivot ~2.025, then R1 ~2.151 and R2 ~2.229.
Pattern-based projection (from similar candlesticks): 70% chance of +1.57% next day, +0.19% next week, +8.72% next month — but this is occurring within an overall bearish structure.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Positioning: Put/Call OI ratio 0.89 = slightly more calls than puts (mildly bullish positioning).
Flow today: Put volume is 0 while call volume is 66 (volume put/call ratio 0.0) — suggests speculative call interest, but on low absolute volume.
Volatility: 30D implied vol ~732.71% (IV percentile ~81.93, IV rank ~68.5) = extremely high uncertainty/pricing of large moves; options market is signaling “event-like” risk even without fresh news.
Volume intensity: Today’s option volume vs 30D avg shows ~440%, indicating unusual attention despite small contract counts.

Technical Summary

Sell

Buy

Positive Catalysts

- Possible technical snapback: RSI is very low, so a short-term bounce is possible if 1.899 support holds.
- Improving YoY financial trend (still loss-making): revenue growth and narrower losses can support sentiment.
- Upcoming earnings catalyst: Next earnings scheduled 2026-02-13 (Pre-Market) could trigger a volatility-driven move (especially given extreme IV).

Neutral/Negative Catalysts

- Primary trend remains bearish: moving averages are stacked bearish and MACD downside momentum is expanding.
- Support is being tested now: price is at/just under S1 ~1.899; failure could quickly expose ~1.821.
- No recent news support: “No news in recent week,” so there’s no clear near-term catalyst to justify buying into a downtrend.
- Extreme implied volatility: options are pricing massive swings, which often coincides with unstable price action rather than clean trend reversals.
- No confirming smart-money signal: hedge funds/insiders reported as neutral; no meaningful trend confirmation from these cohorts.

Financial Performance

Latest quarter: 2025/Q3
- Revenue: $795,950, +104.47% YoY (strong growth off a small base).
- Net income: -$1,246,513, improved +215.76% YoY (still a loss).
- EPS: -0.05, improved +66.67% YoY.
- Gross margin: ~100% (reported), roughly flat YoY.
Takeaway: fundamentals show improving trajectory, but the company remains unprofitable, and the chart currently dominates the near-term timing decision.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating/price target change data was provided, so there is no confirmed recent trend in Wall Street upgrades/downgrades or target revisions.
Wall Street-style pros (based on provided data): improving YoY revenue and loss reduction; potential earnings-driven upside.
Wall Street-style cons (based on provided data): still loss-making, micro-cap profile, and current technical trend is bearish with support under pressure.

Analyst Rating

Wall Street analysts forecast ABVC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABVC is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Buy